Publication | Closed Access

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

MedicinePathologyErlotinib Versus VinorelbineCancer TreatmentCancer GeneticsAdjuvant TherapyOncologyRadiation OncologyLung CancerMolecular OncologyChinese Patients